Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS

British Journal of Haematology

Volumn 102, Issue 3, 1998, Pages 678-683

  Bernasconi, Carlo ^a   Alessandrino, E Paolo ^a   Bernasconi, Paolo ^a   Bonfichi, Maurizio ^a   Lazzarino, Mario ^a   Canevari, Angelo ^a   Castelli, Guglielmo ^a   Brusamolino, Ercole ^a   Pagnucco, Guido ^a   Castagnola, Carlo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chemotherapy; G CSF; MDS; sAML; Survival

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7344222651     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00816.x     Document Type: Article

References (39)

1. Alessandrino, E.P., Bernasconi, P., Bonfichi, M., Caldera, D., Campagnoli, C., Boni, M. & Bernasconi, C. (1993) Bone marrow transplantation from unrelated donor in myelodysplastic syndromes. Bone Marrow Transplantation, 11, (Suppl. 1), 71-73.
2. Anderson, J.E., Anasetti, C., Appelbaum, F.R., Schoch, G., Gooley, T.A., Hansen, J.A., Buckner, C.D., Sanders, J.E., Sullivan, K.M. & Storb, R. (1996a) Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. British Journal of Haematology, 93, 59-67.
3. Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T.R., Clift, R.A., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P. & Storb, R. (1996b) Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood, 87, 51-58.
4. Appelbaum, F.R., Barral, J., Storb, R., Fisher, L.D., Schoch, G., Ramberg, R.E., Shulman, H., Anasetti, C., Bearman, S.I., Beatty, P., Bensinger, W.I., Buckner, C.D., Clift, R.A., Hansen, J.A., Martin, P., Petersen, F.B., Sanders, J.E., Singer, J., Stewart, P., Sullivan, K.M., Witherspoon, R.P. & Thomas, E.D. (1990) Bone marrow transplantation for patients with myelodysplasia: pretreatment variables and outcome. Annals of Internal Medicine, 112, 590-597.
5. Baudard, M., Marie, J.P., Cadion, M., Vignié, F. & Zittoun, R. (1994) Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. British Journal of Haematology, 86, 82-91.
6. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) The French-American-British (FAB) Co-operative Group. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
7. Bernasconi, P., Alessandrino, E.P., Boni, M., Bonfichi, M., Morra, E., Lazzarino, M., Campagnoli, C. & Astori, C. (1994) Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. American Journal of Hematology, 46, 270-277.
8. Celesti, L., Dejana, A., Lerna, E., Fugazza, G., Sessarego, M., Podestà, M., Frassoni, F., Valbonesi, M. & Carella, A.M. (1997) In vivo mobilization of karyotypically normal peripheral blood progenitor cells (PBPC) in high-risk myelodysplastic syndromes. Experimental Hematology, 25, abs. 360.
9. Dastugue, N., Payen, C., Lafage-Pochilatoff, M., Bernard, P., Leroux, D., Huguet-Rigal, F., Stoppa, A.M., Marit, G., Molina, L. & Michallet, M. (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia, 9, 1491-1498.
10. Demuynck, H., Verhoef, G.E.G., Zachee, P., Emonds, M.P., van der Schueren, E., van den Berghe, H., Vanderberghe, P., Casteels-Van Daele, M. & Boogaerts, M.A. (1996) Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical siblings and alternative donors. Bone Marrow Transplantation, 17, 745-741.
11. De Witte, T., Zwaan, F., Hermans, J., Vernant, J., Kolb, H., Vossen, J., Lönnqvist, B., Beelen, D., Ferrant, A., Gmür, J., Yin, L., Troussard, X., Cahn, J., Van Lint, M. & Gratwohl, A. (1990) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). British Journal of Haematology, 74, 151-155.
12. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouadballah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A. & Degos, L., for the AML Cooperative Study Group (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine, 332, 1678-1683.
13. Economopoulos, T., Papageorgiou, E., Stathakis, N., Constantinidou, M., Parharidou, A., Kostourou, A., Dervenoulas, J. & Raptis, S. (1996) Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony stimulating factor (GM-CSF). Leukaemia Research, 20, 385-390.
14. Estey, E.H., Keating, M.J., McCredie, K.B., Bodey, G.P. & Freireich, E.J. (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood, 60, 309-315.
15. Fenaux, P., Morel, P. & Lai, J.L. (1996) Cytogenetics of myelodysplastic syndromes. Seminars in Hematology, 33, 127-138.
16. Ganser, A., Heil, G., Kolbe, K., Maschmeyer, G., Fischer, J.T., Bergmann, L., Mitrou, P.S., Heit, W., Heimpel, H., Huber, C. & Hoelzer, D. (1993a) Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia: initial results. Annals of Hematology, 66, 123-125.
17. Ganser, A., Heil, G., Seipelt, G., Fischer, J. Th., Langer, G., Brockhaus, W., Ittel, T.H., Fuhr, H.G., Bergmann, L. & Hoelzer, D. (1993b) Aggressive induction chemotherapy with idarubicin Ara-C VP-16, followed by G-CSF and maintenance immunotherapy with Interleukin-2 for high-risk ANLL. (Abstract). Blood, 82 (Suppl. 1), 498.
18. Gardin, C., Chaibi, P., De Revel, T., Rousselot, P., Turlure, P., Miclea, J.M., Nedellec, G. & Dombret, H., for the Club de Reflexion e Hematologie (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia. Leukemia, 11, 16-21.
19. Gehan, E.A. (1965) A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika, 52, 203-224.
20. Godwin, J.E., Kopecky, K.J., Head, D.R., Hynes, H.E., Balcerzak, S.P. & Appelbaum, F.R. (1995) A double-blind, placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. (Abstract). Blood, 86, (Suppl. 1), 1723.
21. Haase, D., Fonatsch, C., Freund, M., Wormann, B., Bodenstein, H., Bartels, H., Stollmann-Gibbels, B. & Lengfelder, E. (1995) Cytogenetic findings in 179 patients with myelodysplastic syndromes. Annals of Hematology, 70, 171-187.
22. Holmes, J., Jacobs, A., Carter, G., Janowska-Weiczorek, A. & Padua, R. (1989) Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. British Journal of Haematology, 72, 40-44.
23. Hoyle, C.F., deBastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K., Gray, R. & Hayhoe, F.G. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45-53.
24. ISCN (1995) Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature (ed. by F. Mitelman). S. Karger, Basel.
25. Johnson, P.R.E. & Liu Yin, J.A. (1993) Acute myeloid leukaemia in elderly patients: biology and treatment. British Journal of Haematology, 83, 1-6.
26. Johnson, P.R.E. & Liu Yin, J.A. (1997) The role of granulocyte and granulocyte-macrophage colony stimulating factors in the treatment of acute myeloid leukaemia. British Journal of Haematology, 97, 1-8.
27. Kantarjian, H.M., Estey, E.H. & Keating, M.J. (1993) Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematology/Oncology Clinics of North America, 7, 81-107.
28. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
29. Le Beau, M.M., Espinosa, R., III, Neuman, W.L., Stock, W., Roulston, D., Larson, R.A., Keinanen, M. & Westbrook, C.A. (1993) Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid disease. Proceedings of the National Academy of Sciences of the United States of America, 90, 5484.
30. Longmore, G., Guinan, E.C., Weinstein, H.J., Gelber, R.D., Rappeport, J.M. & Antin, J.H. (1990) Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. Journal of Clinical Oncology, 8, 1707-1714.
31. Löwenberg, B. (1996) Treatment of the elderly patient with acute myeloid leukaemia. Bailliere's Clinical Haematology, 9, 147-159.
32. Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verloef, F.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Shouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M., Zittoun, R., on behalf of EORTC-LCG and HOVON (1997) Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood, 90, 2952-2961.
33. Marie, J.P., Zittoun, R. & Sikic, B.I. (1991) Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592.
34. Morel, P., Hebber, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315-1323.
35. Mufti, G.J. (1992) Primary myelodysplastic syndrome: prognostic value of FAB classification, scoring systems, bone marrow histology and karyotypic analysis. The Myelodysplastic Syndromes (ed. by G. J. Mufti and D. A. G. Galton), pp. 207-223. Churchill Livingstone, New York.
36. Pedersen-Bjergaard, J. & Rowley, J.D. (1994) The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 83, 2780-2786.
37. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennet, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. & Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457-462.
38. Sato, H., Gottesman, M.M., Goldstein, L.J., Pastan, I., Block, A.M., Sandberg, A.A. & Preisler, H.D. (1990) Expression of multidrug resistance gene in myeloid leukemias. Leukemia Research, 14, 11-21.
39. Stone, R.M., Berg, D.D.T., George, S.L., Dodege, R.K., Paciuci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. & Schiffer, C.A., for the Cancer and Leukemia Group B (1995) Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine, 332, 1671-1677.